Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
X
publication

Single-cell mutational profiling enhances the clinical evaluation of AML MRD.


Ediriwickrema, A. et al.
Blood Advances (2020)
Abstract

Although most patients with acute myeloid leukemia (AML) achieve clinical remission with induction chemotherapy, relapse rates remain high. Next-generation sequencing enables minimal/measurable residual disease (MRD) detection; however, clinical significance is limited due to difficulty differentiating between pre-leukemic clonal hematopoiesis and frankly malignant clones. Here, we investigated AML MRD using targeted single-cell sequencing (SCS) at diagnosis, remission, and relapse (n = 10 relapsed, n = 4 nonrelapsed), with a total of 310 737 single cells sequenced. Sequence variants were identified in 80% and 75% of remission samples for patients with and without relapse, respectively. Pre-leukemic clonal hematopoiesis clones were detected in both cohorts, and clones with multiple cooccurring mutations were observed in 50% and 0% of samples. Similar clonal richness was observed at diagnosis in both cohorts; however, decreasing clonal diversity at remission was significantly associated with longer relapse-free survival. These results show the power of SCS in investigating AML MRD and clonal evolution.



Authors

Ediriwickrema, A., Aleshin, A., Reiter, J.G., Corces, M.R., Köhnke, T., Stafford, M., Liedtke, M., Medeiros, B.C., Majeti, R.



VIEW

publication
Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms.
Taylor, J.
Blood (2020)
publication
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma.
Maia, C.
Blood (2020)
publication
Distinct genetic pathways define pre-leukemic and compensatory clonal hematopoiesis in Shwachman-Diamond syndrome
Kennedy, A. L.
BioRxiv (2020)
publication
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.
Choe, S.
Blood Advances (2020)
REQUEST QUOTE